Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.59 |
| ▸ | HPGD | P15428 | 5/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8889074 | 0.86 | KMT2A (0.80) | KMT2AALDH1A1KDM4EHPGDHTT | |
| SCHEMBL220059 | 0.85 | KMT2A (0.72) | KMT2AALDH1A1KDM4EHPGDHTT | |
| SCHEMBL8006673 | 0.83 | KMT2A (0.65) | KMT2AALDH1A1KDM4EHPGDHTT | |
| SCHEMBL1127360 | 0.83 | KMT2A (0.65) | KMT2AALDH1A1KDM4EHPGDHTT | |
| SCHEMBL7869937 | 0.83 | KMT2A (0.65) | KMT2AALDH1A1KDM4EHPGDHTT | |
| SCHEMBL13602477 | 0.82 | ALDH1A1 (0.54) | KMT2AALDH1A1KDM4EHPGDHTT | |
| SCHEMBL647703 | 0.81 | TSHR (0.82) | KMT2AALDH1A1KDM4EHPGDHTT | |
| SCHEMBL27182604 | 0.81 | ELANE (0.51) | KMT2AALDH1A1KDM4EHPGDHTT | |
| SCHEMBL530857 | 0.81 | KMT2A (0.68) | KMT2AALDH1A1KDM4EHPGDHTT | |
| SCHEMBL19221685 | 0.81 | HTT (0.72) | KMT2AALDH1A1KDM4EHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100152255-A1 | Organic Compounds | DAMON ROBERT EDSON | 2010-06-17 | — | — | US | disclosed |
| US-7700637-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | NOVARTIS AG (CH) | 2007-01-04 | — | — | US | disclosed |
| US-5155268-A | Antiarrhythmic N-aminoalkylene alkyl and aryl sulfonamides | THE UPJOHN COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| EP-0164865-B1 | N-(AMINOALKYLPHENYL)SULFONAMIDES THEIR PREPARATION AND THERAPEUTIC USE | THE UPJOHN COMPANY (US) | 1988-12-21 | — | — | EP | disclosed |
| EP-0164865-A1 | N-(Aminoalkylphenyl)sulfonamides their preparation and therapeutic use | THE UPJOHN COMPANY (US) | 1985-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152255-A1 | Organic Compounds | PPARG, FABP2, PPARA | KMT2A 3326/4885ALDH1A1 453/4885KDM4E 4091/4885 |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | PPARG, GPR119, PPARA | KMT2A 1633/4885ALDH1A1 845/4885KDM4E 1746/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | KMT2A 637/4885ALDH1A1 1380/4885KDM4E 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.